According to its updated strategy (Scale To Profit) released in June 2025, OssDsign has decided to invest further in sales and marketing, R&D and clinical studies to spur growth. With the PROPEL data at hand and with the upcoming large Level 1 RCT (200-400 patients), OssDsign is set to address our view that the clinical backing is thin. With strong execution, both growth and operating leverage could be strong in the coming years.
LÄS MER
